Reviewers: Li Liu, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Authors: Koichiro Akakura, Shigeo Isaka, Susumu Akimoto, et al
Source: Urology, 54(2): 313-318, August 1999
External beam radiation therapy has generally been used for patients with locally advanced adenocarcinoma of prostate with or without hormonal therapy. The use of radical prostatectomy for the treatment of locally advanced disease remains controversial. This phase III randomized study offers badly needed information by comparing these two modalities in the treatment of locally advanced prostate cancer.
After 8-week endocrine therapy, patients with stage B2/C prostate cancer were randomized to radical prostatectomy (RP) or external beam radiation therapy (RT) followed by additional endocrine therapy until progression. The majority of patients received daily diethylstilbestrol diphosphate (DES-DP) as endocrine therapy. The RP group contained more patients with clinical stage C disease.
Radical prostatectomy in combination with endocrine therapy appeared to have better progression-free and disease-specific survival rates than radiation for patients with locally advanced prostate cancer, but with a higher price of late morbidities. The endocrine therapy used in this study is not considered standard first line treatment in the US. Longer follow-up is needed to make any definitive conclusions regarding overall survival.Imprima English
Oct 11, 2010 - Radical prostatectomy, external-beam radiotherapy, and brachytherapy result in several quality-of-life issues after prostate cancer treatment in patients not receiving adjuvant hormonal treatment, including either improvement in or worsening of urinary irritative-obstructive symptoms in addition to the more commonly discussed sexual and incontinence issues, according to research published online Oct. 4 in the Journal of Clinical Oncology.
Apr 24, 2014
Jul 28, 2010